XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
  IBS
   Ulcerative Colitis
  Liver
  GERD
  Constipation
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

IBS Channel
subscribe to IBS newsletter

Latest Research : Gastroenterology : IBS

   DISCUSS   |   EMAIL   |   PRINT
Certolizumab Shows Significant Benefit in Moderate to Severe Crohn’s Disease
Jul 27, 2005, 14:11, Reviewed by: Dr.

“These results are highly encouraging, showing a significant potential to address the considerable unmet medical need in the treatment of Crohn’s disease and to bring new hope to the hundreds of thousands of patients affected by this debilitating disease."

 
UCB today announced significant positive results for the two pivotal phase III trials (PRECISE 1 and 2) of CIMZIATM (certolizumab pegol, CDP870) in the induction and maintenance of clinical response in moderate to severe active Crohn’s disease. The PRECiSE trials assessed the safety and efficacy of CIMZIA compared to placebo over a 26 week period, in a total of 1330 patients with active Crohn’s disease.

The primary endpoints in both the PRECiSE 1 and PRECiSE 2 trials were met with statistical significance, irrespective of C-reactive protein (CRP, a marker of inflammation) status or prior exposure to anti-TNF therapy. In addition, data from both trials suggest CIMZIATM is well-tolerated.

CIMZIATM is therefore the first subcutaneously-administered anti-TNF biologic to successfully meet the primary endpoints in a phase III clinical trial programme in Crohn's disease.

A regulatory submission for CIMZIATM in the treatment of Crohn’s disease is scheduled to be submitted in both the US and Europe within the next six to nine months.

“These results are highly encouraging, showing a significant potential to address the considerable unmet medical need in the treatment of Crohn’s disease and to bring new hope to the hundreds of thousands of patients affected by this debilitating disease”, commented Prof. William Sandborn, Mayo Clinic College of Medicine, Rochester, Minnesota, USA, principal investigator on the PRECiSE 1 trial. “The results from the PRECiSE trials suggest CIMZIA to be highly effective at reducing the symptoms associated with Crohn’s disease”.

Dr. Stefan Schreiber, principal investigator on the PRECiSE 2 trial, and Professor of Medicine and Gastroenterology at the Christian-Albrechts University, Kiel, Germany, further highlighted the advantages of CIMZIATM in “offering highly convenient dosing with a patient-friendly, subcutaneous route of administration, having the potential to improve the long-term management of this lifelong disease”.

Data from PRECiSE 1 and 2 will be presented in more detail at the major forthcoming gastroenterology congresses.

“The findings of the PRECiSE trials are consistent with our vision of changing patients lives for the better”, said Roch Doliveux, CEO, UCB. “With the robust clinical results and its subcutaneous administration, CIMZIATM has the potential to have a significant impact on the treatment of Crohn’s disease”.

About Crohn’s disease

Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract with the disease typically localized in the terminal part of the ileum and right colon. Crohn’s disease affects almost 1 million patients worldwide, with the disease typically appearing early in life.

About CIMZIATM

CIMZIATM is a unique anti-TNF biologic. CIMZIATM is a PEGylated Fab’ fragment of a humanised anti-TNF ? monoclonal antibody, with high affinity for both soluble and membrane-bound TNF ?. CIMZIATM is currently the subject of phase III clinical trials in both Crohn’s disease and rheumatoid arthritis.
 

- UCB
 

www.ucb-group.com

 
Subscribe to IBS Newsletter
E-mail Address:

 

About UCB

UCB (www.ucb-group.com) is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specialising in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders, as well as oncology. UCB key products are Keppra® (antiepileptic), Xyzal® and Zyrtec® (antiallergics), Nootropil® (cerebral function regulator), Tussionex™ (antitussive) and Metadate™ / Equasym XL™ (attentiondeficit/ hyperactivity disorder). UCB employs over 8,500 people operating in over 40 countries. UCB is listed on Euronext Brussels with a market capitalization of approximately € 5.8 billion.

For enquiries, please contact:

Jean-Christophe Donck
Vice President
Corporate Communication & Investor Relations
Phone +32 2 559 9588
Fax +32 2 559 9571
Email


Related IBS News

Why smokers rarely suffer from ulcerative colitis
Exercise, eating right could ease IBS, diarrhea and constipation
Budesonide Prolongs Remission of Crohn's Disease
Genome wide approach to pinpoint gene activations in IBD
Certolizumab Shows Significant Benefit in Moderate to Severe Crohn’s Disease
Probiotic bacteria mixture VSL#3 ease ulcerative colitis pain
Pediatric Researchers Collaborate to Build Largest Inflammatory Bowel Disease Registry
Irritable bowel syndrome, frequent indigestion common in people with insomnia


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us